We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intelligent Medicine Acquisition Corporation | NASDAQ:IQMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.04 | 10.81 | 11.10 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2023
INTELLIGENT MEDICINE ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
Delaware | 001-41024 | 86-2283527 |
(State
or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
9001 Burdette Rd.
Bethesda, MD 20817
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (202) 905-5834
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange
on which registered | ||
Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-half of one redeemable warrant | IQMDU | The Nasdaq Stock Market LLC | ||
Shares of Class A common stock included as part of the units | IQMD | The Nasdaq Stock Market LLC | ||
Redeemable warrants included as part of the units, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 | IQMDW | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 | Other Events |
On April 26, 2023, Intelligent Medicine Acquisition Corp. (the “Company”) issued a press release announcing that, because it does not believe it can consummate an initial combination within the time period required by its Amended and Restated Certificate of Incorporation (the “Charter”), it intends to dissolve and liquidate in accordance with the provisions of the Charter and will redeem all of its remaining shares of Class A common stock that were included in the units issued in its initial public offering. In addition, the Company no longer intends to proceed with respect to the hearing before the Nasdaq Hearings Panel to appeal Nasdaq’s determination that the Company no longer meets certain listing standards. As a result, Nasdaq will suspend trading of the Company’s shares at the open of business on April 27, 2023, and the Company expects that Nasdaq will proceed with delisting the Company’s securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits:
Exhibit | Description | |
99.1 | Press Release dated April 26, 2023 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Intelligent Medicine Acquisition Corp | ||
Date: April 26, 2023 | By: | /s/ Gregory C. Simon |
Name: Gregory C. Simon | ||
Title: Chief Executive Officer |
1 Year Intelligent Medicine Acq... Chart |
1 Month Intelligent Medicine Acq... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions